Esther Artime1, Irene Romera2, Silvia Díaz-Cerezo2, Elías Delgado3,4,5,6. 1. Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain. artime_esther@lilly.com. 2. Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain. 3. Department of Endocrinology and Nutrition, University of Oviedo, Oviedo, Spain. 4. Central University Hospital of Asturias, Oviedo, Spain. 5. Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Spain. 6. Spanish Biomedical Research Network in Rare Diseases, Madrid, Spain.
Abstract
INTRODUCTION: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with type 2 diabetes mellitus (T2DM). The objectives of this systematic literature review were to identify and synthesize published data describing the epidemiology and mortality of CVD in the T2DM population and the associated economic burden. METHODS: We conducted a systematic review searching the PubMed and MEDES databases from 2009 to 2019 using predefined selection criteria. Peer-reviewed observational studies reporting primary or secondary data on CVD prevalence, incidence, mortality, resource use and costs in patients with T2DM in Spain, written in English and Spanish, were included. Data were tabulated and summarized descriptively. RESULTS: Of 706 articles identified, 52 were included in the review. Most studies were based on data from hospital discharge databases and registries. The reported prevalence of CVD among patients with T2DM ranged from 6.9 to 40.8%. The prevalence of coronary heart disease ranged from 4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 13.0%, and heart failure from 4.3 to 20.1%. In-hospital CVD mortality rates ranged from 5.6 to 10.8%. Direct costs due to CVD in hospitalized patients with T2DM were increased (> 50%) compared with patients without CVD. No studies analysed indirect costs of CVD in patients with T2DM. CONCLUSIONS: The burden of CVD among patients with T2DM, combined with the elevated costs of care, highlights the importance of early prevention as part of integrated management of the disease to improve clinical and economic outcomes.
INTRODUCTION:Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with type 2 diabetes mellitus (T2DM). The objectives of this systematic literature review were to identify and synthesize published data describing the epidemiology and mortality of CVD in the T2DM population and the associated economic burden. METHODS: We conducted a systematic review searching the PubMed and MEDES databases from 2009 to 2019 using predefined selection criteria. Peer-reviewed observational studies reporting primary or secondary data on CVD prevalence, incidence, mortality, resource use and costs in patients with T2DM in Spain, written in English and Spanish, were included. Data were tabulated and summarized descriptively. RESULTS: Of 706 articles identified, 52 were included in the review. Most studies were based on data from hospital discharge databases and registries. The reported prevalence of CVD among patients with T2DM ranged from 6.9 to 40.8%. The prevalence of coronary heart disease ranged from 4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 13.0%, and heart failure from 4.3 to 20.1%. In-hospital CVDmortality rates ranged from 5.6 to 10.8%. Direct costs due to CVD in hospitalized patients with T2DM were increased (> 50%) compared with patients without CVD. No studies analysed indirect costs of CVD in patients with T2DM. CONCLUSIONS: The burden of CVD among patients with T2DM, combined with the elevated costs of care, highlights the importance of early prevention as part of integrated management of the disease to improve clinical and economic outcomes.
Entities:
Keywords:
Burden of disease; Cardiovascular disease; Costs; Diabetes mellitus, type 2; Incidence; Mortality; Prevalence
Authors: Alan J Garber; Yehuda Handelsman; George Grunberger; Daniel Einhorn; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Michael A Bush; Ralph A DeFronzo; Jeffrey R Garber; W Timothy Garvey; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Leigh Perreault; Paul D Rosenblit; Susan Samson; Guillermo E Umpierrez Journal: Endocr Pract Date: 2020-01 Impact factor: 3.443
Authors: Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse Journal: Diabetologia Date: 2018-12 Impact factor: 10.122
Authors: John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies Journal: Diabetes Care Date: 2019-12-19 Impact factor: 17.152
Authors: Lorenzo M Vetrone; Francesco Zaccardi; David R Webb; Sam Seidu; Nitin N Gholap; Dario Pitocco; Melanie J Davies; Kamlesh Khunti Journal: Acta Diabetol Date: 2018-11-19 Impact factor: 4.280
Authors: Karen Jordan; Christopher G Fawsitt; Paul G Carty; Barbara Clyne; Conor Teljeur; Patricia Harrington; Mairin Ryan Journal: Eur J Health Econ Date: 2022-07-22
Authors: Stefan Strilciuc; Diana Alecsandra Grad; Constantin Radu; Diana Chira; Adina Stan; Marius Ungureanu; Adrian Gheorghe; Fior-Dafin Muresanu Journal: J Med Life Date: 2021 Sep-Oct
Authors: Jakub Benko; Matej Samoš; Tomáš Bolek; Dana Prídavková; Jakub Jurica; Martin Jozef Péč; Peter Galajda; Marián Mokáň Journal: J Diabetes Res Date: 2022-03-07 Impact factor: 4.011